ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
Overall ORGO gets a fundamental rating of 5 out of 10. We evaluated ORGO against 559 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. ORGO has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ORGO had positive earnings in the past year.
ORGO had a positive operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
In the past 5 years ORGO always reported a positive cash flow from operatings.
1.2 Ratios
ORGO has a Return On Assets of -4.37%. This is amongst the best in the industry. ORGO outperforms 87.66% of its industry peers.
ORGO's Return On Equity of -5.55% is amongst the best of the industry. ORGO outperforms 89.98% of its industry peers.
The Return On Invested Capital of ORGO (1.02%) is better than 91.95% of its industry peers.
ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROIC | 1.02% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO has a Operating Margin of 1.13%. This is amongst the best in the industry. ORGO outperforms 92.13% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 75.85%, ORGO belongs to the top of the industry, outperforming 83.90% of the companies in the same industry.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
ORGO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.79 indicates that ORGO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.79, ORGO is in the better half of the industry, outperforming 75.85% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, ORGO perfoms like the industry average, outperforming 46.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.79 |
ROIC/WACC0.1
WACC10%
2.3 Liquidity
A Current Ratio of 4.12 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Current ratio (4.12) which is in line with its industry peers.
ORGO has a Quick Ratio of 3.67. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a Quick ratio of 3.67. This is comparable to the rest of the industry: ORGO outperforms 44.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
The earnings per share for ORGO have been decreasing by -37.90% on average. This is quite bad
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 5.36%.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
3.2 Future
Based on estimates for the next years, ORGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.13% on average per year.
ORGO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.53% yearly.
EPS Next Y-77.5%
EPS Next 2Y0%
EPS Next 3Y12.13%
EPS Next 5YN/A
Revenue Next Year4.16%
Revenue Next 2Y8.23%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 35.22 indicates a quite expensive valuation of ORGO.
Based on the Price/Earnings ratio, ORGO is valued cheaper than 93.74% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.60, ORGO is valued a bit more expensive.
With a Price/Forward Earnings ratio of 18.65, ORGO is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 92.84% of the companies listed in the same industry.
ORGO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.22 | ||
| Fwd PE | 18.65 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 95.71% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 13.04 |
4.3 Compensation for Growth
ORGO has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 12.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y12.13%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.17
-0.08 (-2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners50.15%
Inst Owner Change4.51%
Ins Owners30.6%
Ins Owner Change1.17%
Market Cap402.11M
Analysts82
Price Target6.38 (101.26%)
Short Float %17.81%
Short Ratio7.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)248.79%
Min EPS beat(2)-73%
Max EPS beat(2)570.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)13.3%
Revenue beat(4)3
Avg Revenue beat(4)3.87%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.9%
Revenue beat(12)5
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)0.94%
PT rev (1m)4.17%
PT rev (3m)13.64%
EPS NQ rev (1m)-200%
EPS NQ rev (3m)-300%
EPS NY rev (1m)0%
EPS NY rev (3m)150%
Revenue NQ rev (1m)-0.98%
Revenue NQ rev (3m)-25.01%
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)2.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.22 | ||
| Fwd PE | 18.65 | ||
| P/S | 0.88 | ||
| P/FCF | N/A | ||
| P/OCF | 90.67 | ||
| P/B | 1.09 | ||
| P/tB | 1.23 | ||
| EV/EBITDA | 13.04 |
EPS(TTM)0.09
EY2.84%
EPS(NY)0.17
Fwd EY5.36%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.03
OCFY1.1%
SpS3.62
BVpS2.9
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROCE | 1.29% | ||
| ROIC | 1.02% | ||
| ROICexc | 1.4% | ||
| ROICexgc | 1.63% | ||
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 65.96% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 1.44 | ||
| Cash Conversion | 19.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 3.79 |
F-Score6
WACC10%
ROIC/WACC0.1
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-77.5%
EPS Next 2Y0%
EPS Next 3Y12.13%
EPS Next 5YN/A
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year4.16%
Revenue Next 2Y8.23%
Revenue Next 3Y10.53%
Revenue Next 5YN/A
EBIT growth 1Y-59.06%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y57.36%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3Y-38.8%
OCF growth 5YN/A